HIV-1 Envelope, Human Immunodeficiency Virus Antigen, Recombinant
| Full Name |
HIV-1 Envelope, Human Immunodeficiency Virus Antigen, Recombinant
|
Abbreviated Name-1 |
HIV-I envelope; |
| Documents |
|---|
| Figures |
|---|
| Reference |
|---|
Decroly E, et al. The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). J. Biol. Chem. Apr 1994; 269(16): 12240-12247.
VanCott TC, et al. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. Oct 1995; 155(8): 4100-4110.
Pincus SH, et al. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J. Immunol. Apr 1997; 158(7): 3511-3520.
|
|
Description |
E. coli-derived GenScript Human Immunodeficiency Virus (HIV)-1 Envelope spanning the C-Terminus of gp120 and most of gp41. Superior diagnostic reagent for HIV-1 and HIV type-O detection. Detects all HIV-1 and HIV-type O infected individuals responding to envelope proteins. |
Source |
E. coli |
Purity |
Protein is >95% pure as determined by 10% PAGE (coomassie staining). |
Storage |
Protein is shipped at ambient temperature. Upon arrival, store at +4°C.
|
Concentration |
•1 mg/ml in 50 mM Tris. pH8.0, containing 0.1% SDS, 5 mM DTT, and 2.5 mM EDTA. (Proper for ELISA)
•3 mg/ml in 8 M Urea, 20 mM Tris-HCl, 1 mM EDTA, 10 mM b-mercaptoethanol, pH8. (Proper for membrane applications)
•3 mg/ml in 10 mM Citrate pH3.0. (Proper for ELISA) |
Stability |
Five years frozen. Four months in solution at room temperature. |
Specificity |
Immunoreactive with all sera of HIV-1 and HIV-type O infected individuals and with 60-80% of HIV-2 infected individuals. |
Applications |
Antigen in ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems. |
Note |
; |
Related Products
 |
1 |
Custom Recombinant Protein Services: Guaranteed E. coli Expression Package-3 mg purified soluble protein from $2,200 . |
2 |
Bacterial Expression System: GenScript has developed BacPowerTM technologies to tackle hard-to-express and hard-to-dissolve proteins. |
3 |
Yeast Expression System: GenScript's proprietary YeastHIGHTM technology combines the advantages of the bacterial and eukaryotic expression systems. |
4 |
Baculovirus/Insect Cell Expression System: GenScript developed BacuVanceTM platform for the secretion of recombinant proteins from baculovirus-infected insect cells. |
5 |
Mammalian Cell Expression System: The proprietary 293 and CHO suspension system platform promotes fast production and delivery of recombinant proteins and monoclonal antibodies up to grams level. |
|
